Lipid Nanoparticles for Drug Delivery, Imaging, and Modeling Disease

TOPICAL COLLECTIONS

Guest Editors

Jiansheng Huang

Vanderbilt University Medical Center, Division of Cardiovascular Medicine

Dr. Jiansheng Huang graduated from Auburn University, Harrison School of Pharmacy in 2015 and is currently a research fellow in the Division of Cardiovascular Medicine at Vanderbilt University Medical Center. Jiansheng has a scientific research background in the interdisciplinary fields of cardiovascular medicine, lipid metabolism, macrophage biology, chronic metabolic diseases. Dr. Huang also serves on the editorial board of the journal Frontiers in Pharmacology. His recent work is mainly focused on the study of the pathogenesis of atherosclerosis, type II diabetes, and cardiovascular drug development. Jiansheng has published about 20 papers in top international journals such as Nature Communications, Clinical and Translational Medicine, Seminars in Cancer Biology, Annual Reviews: Pharmacology& Toxicology, and Journal of Leukocyte Biology in the past five years.

Hui Huang

Vanderbilt University, Center of Structural Biology

Dr. Hui Huang, graduated from Auburn University, School of Veterinary Medicine in 2014 and is currently a research instructor in the Center of Structural Biology at Vanderbilt University. Dr. Huang has a scientific research background in the interdisciplinary fields of pathophysiological roles of KCNQ1 in cardiac arrhythmia, and structural and functional studies of G-protein coupled receptors in obesity. Dr. Huang’s recent work is mainly focused on studying the mechanisms of KCNQ1 channel dysfunction in long QT syndrome involving voltage sensor domain mutations. Dr. Huang has published about 20 papers in the top international journals such as Science Advances, Elife, Chemical Reviews, Clinical and Translational Medicine in the past five years.

Collection Overview

Lipid nanoparticles-based drug delivery and therapeutics-both have been widely studied in the past few decades. The advantages of lipid nanoparticles are to promote transport across the cell membranes, and to increase the safety and efficacy of drugs, thereby improving the stability and delivery specificity of targeted drugs or mRNAs. Lipid nanoparticles have the remarkable ability to improve chronic disease diagnosis and therapeutic specificity. Lipid nanoparticles have also been widely studied and have generated promising results in vitro and small animal models. This proposed Methods Collection aims to focus on the development of lipid nanoparticles and molecular imaging probes, and their applications for drug delivery and in vivo molecular imaging. Besides, extensive research efforts on lipid nanoparticles and rHDL have been implicated in chronic inflammatory diseases. Reconstituted HDL or synthetic lipid nanoparticles have been developed for specific drug delivery to tissues such as muscles, liver, prostate, artery walls, and brain in animal models. Therefore, studies on nanoparticle related in vitro and in vivo disease models of inflammatory disease are also welcome. This proposed Methods Collection aims to focus on 1) the development of lipid nanoparticles and molecular imaging probes for drug delivery and in vivo molecular imaging; 2) to study the molecular mechanisms of cardiometabolic diseases using in vitro or in vivo models.